Clofoctol is a bacteriostatic antibiotic. It is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria.[1] It has been marketed in France till 2005 under the trade name Octofene and in Italy as Gramplus.[citation needed]
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Rectal (suppository)[1] |
ATC code |
|
Pharmacokinetic data | |
Bioavailability | 98%[1] |
Metabolism | Hepatic glucuronidation[1] |
Excretion | Biliary[1] |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.048.739 |
Chemical and physical data | |
Formula | C21H26Cl2O |
Molar mass | 365.34 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(verify) |
It is only functional against Gram-positive bacteria.[2]
It penetrates into human lung tissue.[3]
A French company, Apteeus had been developing clofoctol as a potential therapy against SARS-CoV-2 in 2020-2021, but eventually the repurposing of the drug was abandoned, due to a lack of volunteers.[4][5]